Activation of CB2 cannabinoid receptors by AM1241 inhibits experimental neuropathic pain: pain inhibition by receptors not present in the CNS
about
CB2 cannabinoid receptor activation produces antinociception by stimulating peripheral release of endogenous opioidsIn vitro pharmacological characterization of AM1241: a protean agonist at the cannabinoid CB2 receptor?A cannabinoid 2 receptor agonist attenuates bone cancer-induced pain and bone lossIs lipid signaling through cannabinoid 2 receptors part of a protective system?Crucial role of CB(2) cannabinoid receptor in the regulation of central immune responses during neuropathic painIn vitro and in vivo characterization of A-796260: a selective cannabinoid CB2 receptor agonist exhibiting analgesic activity in rodent pain modelsTargeting the cannabinoid CB2 receptor: modelling and structural determinants of CB2 selective ligandsDifferential effects of cannabinoid receptor agonists on regional brain activity using pharmacological MRI.The endocannabinoid system as an emerging target of pharmacotherapySpecies-specific in vitro pharmacological effects of the cannabinoid receptor 2 (CB2) selective ligand AM1241 and its resolved enantiomersNovel cannabinoid receptorsMinireview: From the bench, toward the clinic: therapeutic opportunities for cannabinoid receptor modulationTherapeutic potential of monoacylglycerol lipase inhibitorsExpression Analysis of CB2-GFP BAC Transgenic MiceThe CB2 receptor and its role as a regulator of inflammationPharmacotherapeutic modulation of the endocannabinoid signalling system in psychiatric disorders: drug-discovery strategiesModulation of trigeminal sensory neuron activity by the dual cannabinoid-vanilloid agonists anandamide, N-arachidonoyl-dopamine and arachidonyl-2-chloroethylamideStabilized epoxygenated fatty acids regulate inflammation, pain, angiogenesis and cancerTargeting cannabinoid agonists for inflammatory and neuropathic painBrain neuronal CB2 cannabinoid receptors in drug abuse and depression: from mice to human subjectsEffects of a selective cannabinoid CB2 agonist and antagonist on intravenous nicotine self administration and reinstatement of nicotine seekingFunctional expression of brain neuronal CB2 cannabinoid receptors are involved in the effects of drugs of abuse and in depressionEndocannabinoid system and psychiatry: in search of a neurobiological basis for detrimental and potential therapeutic effects.COX-2, CB2 and P2X7-immunoreactivities are increased in activated microglial cells/macrophages of multiple sclerosis and amyotrophic lateral sclerosis spinal cord.Recent data on cannabinoids and their pharmacological implications in neuropathic pain.Targeted zwitterionic near infrared fluorescent probe for improved imaging of type 2 cannabinoid receptors.Brain CB₂ Receptors: Implications for Neuropsychiatric Disorders.Antinociceptive effects of racemic AM1241 and its chirally synthesized enantiomers: lack of dependence upon opioid receptor activation.2012 Division of medicinal chemistry award address. Trekking the cannabinoid road: a personal perspectiveForced exercise attenuates neuropathic pain in chronic constriction injury of male rat: an investigation of oxidative stress and inflammationCannabinoids as pharmacotherapies for neuropathic pain: from the bench to the bedsideSynthesis and pharmacology of 1-methoxy analogs of CP-47,497.CB2: a cannabinoid receptor with an identity crisisPharmacological characterization of a novel cannabinoid ligand, MDA19, for treatment of neuropathic painPathogenesis of spinal cord injury induced edema and neuropathic pain: expression of multiple isoforms of wnk1.Celastrol attenuates inflammatory and neuropathic pain mediated by cannabinoid receptor type 2.Treatment with a cannabinoid receptor 2 agonist decreases severity of established cystitisCB2 Cannabinoid receptors as a therapeutic target-what does the future hold?1-Bromo-3-(1',1'-dimethylalkyl)-1-deoxy-Δ(8)-tetrahydrocannabinols: New selective ligands for the cannabinoid CB(2) receptor.Chronic cannabinoid receptor 2 activation reverses paclitaxel neuropathy without tolerance or cannabinoid receptor 1-dependent withdrawal
P2860
Q24556619-2582DA51-5669-461C-87A9-3EAB8FA2D3F9Q24564956-02B95EA3-D546-459C-A75D-9D1F474ED5ADQ24615787-823F5311-E782-4C79-A560-27379676A17DQ24633122-FA48790D-4FF3-4C34-80C7-93D1544B0FEAQ24634161-0B2C2AAD-0167-41AB-9557-05E6EF200B8BQ24643672-461C5D86-65A6-483F-BA52-D5D89B2BEC7BQ24643941-5EE242FB-40A0-47A8-8ACC-89EDDAFCF10EQ24643957-A23F0A02-02BA-42E5-9672-2F07240E36DFQ24648473-66C5B6E3-9D41-4B67-A609-962B0B7C2B77Q24673335-63AE115E-9D4F-4BF6-8CD3-ADA832177ACEQ24681482-F50B43BE-C968-40C2-8F17-A318D9BE47E5Q26829111-A23029E7-A35F-42E7-9BF3-02F5CC7C2C29Q26991513-92712007-0198-4415-A26D-FE1D85F6E26DQ27316448-59C82293-3F4C-45F0-A652-A95A6F49F8BFQ28066700-4C274428-47E0-4714-8E19-376AA82D9506Q28241318-52C0D78E-1228-4F89-9931-3D3F8F186D74Q28248981-87E87980-AEA5-474C-B2B3-5011B8B7EA45Q28304230-C4585A4E-597D-4F73-B7D1-199EF133CF74Q28307619-85155B34-BB9A-4A39-9831-25AD6E487C77Q28472191-40062417-60A7-4790-BF27-20FE2B678926Q28480387-B4CA8BC5-AC68-4B9F-9A89-DB68B7AB9446Q28566269-FBF11748-B6BF-41D8-8137-53BECABBE80EQ30473707-791273E5-46E9-4570-8212-A93CF6400CC0Q33235278-2BBE3D0B-419D-432E-9FB5-0EB6C38A48E2Q33527067-3385E1EB-C73D-4997-BC90-08EDEB8CEFDBQ33604098-01818D00-C8E1-4912-A129-D70C3085670AQ33664105-099D90C5-4CC2-4E81-BCAC-A4AFC6B6ACD0Q33749455-85C91B4B-F0AC-42E1-A1A6-F444488D6B4BQ33781776-311BC4F6-C7F8-405D-8C51-4E6E4E955E86Q33879278-AA1C6BC5-76F1-4062-BC66-34A64F3F7DBAQ34019573-13F75A21-AD6B-4739-A5F9-65449C73C4F8Q34059803-7AEEEF5E-38CD-44C5-9F9A-EBD24FA81959Q34098185-981D1F28-F48F-46E8-B11D-4B66AF4D4A4AQ34118976-B2CF84C2-F61E-4F69-9E29-A06E2C7D6C43Q34153895-2C9245D5-6D27-48B6-8B0E-CBFD6A43A5FFQ34158418-FBFFD8C5-7652-48B5-A39E-C5F4EB976BF1Q34176058-1F56C29B-01AF-492B-ADA3-60603F9F2C31Q34186015-1B77919A-C5CE-48E9-90F9-879715C6CC7BQ34298682-43EE0A13-0F99-4170-83DD-BEB9D78C20EAQ34403197-AE134181-2A0A-4CEE-839D-281AB0FAA661
P2860
Activation of CB2 cannabinoid receptors by AM1241 inhibits experimental neuropathic pain: pain inhibition by receptors not present in the CNS
description
2003 nî lūn-bûn
@nan
2003 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած
@hyw
2003 թվականի սեպտեմբերին հրատարակված գիտական հոդված
@hy
2003年の論文
@ja
2003年論文
@yue
2003年論文
@zh-hant
2003年論文
@zh-hk
2003年論文
@zh-mo
2003年論文
@zh-tw
2003年论文
@wuu
name
Activation of CB2 cannabinoid ...... ceptors not present in the CNS
@ast
Activation of CB2 cannabinoid ...... ceptors not present in the CNS
@en
Activation of CB2 cannabinoid ...... ceptors not present in the CNS
@nl
type
label
Activation of CB2 cannabinoid ...... ceptors not present in the CNS
@ast
Activation of CB2 cannabinoid ...... ceptors not present in the CNS
@en
Activation of CB2 cannabinoid ...... ceptors not present in the CNS
@nl
prefLabel
Activation of CB2 cannabinoid ...... ceptors not present in the CNS
@ast
Activation of CB2 cannabinoid ...... ceptors not present in the CNS
@en
Activation of CB2 cannabinoid ...... ceptors not present in the CNS
@nl
P2093
P2860
P50
P921
P3181
P356
P1476
Activation of CB2 cannabinoid ...... ceptors not present in the CNS
@en
P2093
Alexander Zvonok
Debra A Cockayne
Heriberto P Mata
Hongfeng Deng
Joyce Kwan
Mohab M Ibrahim
T Philip Malan
Todd W Vanderah
P2860
P304
P3181
P356
10.1073/PNAS.1834309100
P407
P577
2003-09-02T00:00:00Z